Patricia D Jones1,2, Carlos Diaz3, Danlu Wang4, Joselin Gonzalez-Diaz5, Paul Martin5,6, Erin Kobetz6,7,8. 1. Division of Hepatology, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. pdjones@med.miami.edu. 2. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. pdjones@med.miami.edu. 3. Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. 4. Department of Medicine, University of Miami Miller School of Medicine/JFK Medical Center Palm Beach Regional GME Consortium, Miami, FL, 33136, USA. 5. Division of Hepatology, Department of Medicine, University of Miami Miller School of Medicine, 1120 NW 14th Street, Miami, FL, 33136, USA. 6. Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. 7. Division of Computational Medicine and Population Health, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, 33136, USA. 8. Jay Weiss Institute for Health Equity, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, 33136, USA.
Abstract
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) incidence is increasing at differential rates depending on race. We aimed to identify associations between race and survival after HCC diagnosis in a diverse American population. METHODS: Using the cancer registry from Sylvester Comprehensive Cancer Center, University of Miami and Jackson Memorial Hospitals, we performed retrospective analysis of 999 patients diagnosed with HCC between 9/24/2004 and 12/19/2014. We identified clinical characteristics by reviewing available electronic medical records. The association between race and survival was analyzed using Cox proportional hazards regression. RESULTS: Median survival in days was 425 in Blacks, 904.5 in non-Hispanic Whites, 652 in Hispanics, 570 in Asians, and 928 in others, p < 0.01. Blacks and Asians presented at more advanced stages with larger tumors. Although Whites had increased severity of liver disease at diagnosis compared to other races, they had 36% reduced rate of death compared to Blacks, [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.51-0.8, p < 0.01]. After adjusting for significant covariates, Whites had 22% (HR 0.78, 95% CI 0.61-0.99, p 0.04) reduced risk of death, compared to Blacks. Transplant significantly reduced rate of death; however, only 13.3% of Blacks had liver transplant, compared to 40.1% of Whites, p < 0.01. CONCLUSIONS: In this diverse sample of patients, survival among Blacks is the shortest after HCC diagnosis. Survival differences reflect a more advanced tumor stage at presentation rather than severity of underlying liver disease precluding treatment. Improving survival in minority populations, in whom HCC incidence is rapidly increasing, requires identification and modification of factors contributing to late-stage presentation.
BACKGROUND AND AIMS: Hepatocellular carcinoma (HCC) incidence is increasing at differential rates depending on race. We aimed to identify associations between race and survival after HCC diagnosis in a diverse American population. METHODS: Using the cancer registry from Sylvester Comprehensive Cancer Center, University of Miami and Jackson Memorial Hospitals, we performed retrospective analysis of 999 patients diagnosed with HCC between 9/24/2004 and 12/19/2014. We identified clinical characteristics by reviewing available electronic medical records. The association between race and survival was analyzed using Cox proportional hazards regression. RESULTS: Median survival in days was 425 in Blacks, 904.5 in non-Hispanic Whites, 652 in Hispanics, 570 in Asians, and 928 in others, p < 0.01. Blacks and Asians presented at more advanced stages with larger tumors. Although Whites had increased severity of liver disease at diagnosis compared to other races, they had 36% reduced rate of death compared to Blacks, [hazard ratio (HR) 0.64, 95% confidence interval (CI) 0.51-0.8, p < 0.01]. After adjusting for significant covariates, Whites had 22% (HR 0.78, 95% CI 0.61-0.99, p 0.04) reduced risk of death, compared to Blacks. Transplant significantly reduced rate of death; however, only 13.3% of Blacks had liver transplant, compared to 40.1% of Whites, p < 0.01. CONCLUSIONS: In this diverse sample of patients, survival among Blacks is the shortest after HCC diagnosis. Survival differences reflect a more advanced tumor stage at presentation rather than severity of underlying liver disease precluding treatment. Improving survival in minority populations, in whom HCC incidence is rapidly increasing, requires identification and modification of factors contributing to late-stage presentation.
Authors: Fatma M Shebl; David E Capo-Ramos; Barry I Graubard; Katherine A McGlynn; Sean F Altekruse Journal: Cancer Epidemiol Biomarkers Prev Date: 2012-06-05 Impact factor: 4.254
Authors: Avo Artinyan; Brian Mailey; Nicelio Sanchez-Luege; Joshua Khalili; Can-Lan Sun; Smita Bhatia; Lawrence D Wagman; Nicholas Nissen; Steven D Colquhoun; Joseph Kim Journal: Cancer Date: 2010-03-01 Impact factor: 6.860
Authors: Nathaniel Jembere; Michael A Campitelli; Morris Sherman; Jordan J Feld; Wendy Lou; Stuart Peacock; Eric Yoshida; Murray D Krahn; Craig Earle; Hla-Hla Thein Journal: PLoS One Date: 2012-07-13 Impact factor: 3.240
Authors: Adam C Winters; Julie C Sung; Brooke Wyatt; Deeva Berera; Thomas D Schiano; Myron E Schwartz; Ponni V Perumalswami; Andrea D Branch Journal: Clin Liver Dis (Hoboken) Date: 2018-11-06
Authors: Angelica D'Aiello; Numa Rahman; N Patrik Brodin; Manish Dave; Sakshi Jasra; Andreas Kaubisch; Rafi Kabarriti; Jennifer Chuy Journal: J Gastrointest Cancer Date: 2022-05-09
Authors: Ponni V Perumalswami; Brooke Wyatt; Chip A Bowman; Krupa Patel; Anna Mageras; Sara C Lewis; Andrea D Branch Journal: Cancer Med Date: 2022-03-09 Impact factor: 4.711
Authors: Nicole E Rich; Christian Carr; Adam C Yopp; Jorge A Marrero; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2020-12-30 Impact factor: 11.382
Authors: Tali Shaltiel; Serena Zheng; Cleo Siderides; Elizabeth M Gleeson; Jacquelyn Carr; Eric R Pletcher; Noah A Cohen; Benjamin J Golas; Deepa R Magge; Daniel M Labow; Andrea D Branch; Umut Sarpel Journal: Cancer Date: 2021-02-25 Impact factor: 6.921